NasdaqGM:ZGNX

Stock Analysis Report

Executive Summary

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States.

Snowflake

Fundamentals

Excellent balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Zogenix's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.5%

ZGNX

1.2%

US Pharmaceuticals

-0.6%

US Market


1 Year Return

-15.7%

ZGNX

-8.4%

US Pharmaceuticals

0.7%

US Market

ZGNX underperformed the Pharmaceuticals industry which returned -8.4% over the past year.

ZGNX underperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

ZGNXIndustryMarket
7 Day-0.5%1.2%-0.6%
30 Day-17.2%1.8%2.9%
90 Day1.6%-4.3%1.3%
1 Year-15.7%-15.7%-6.2%-8.4%2.9%0.7%
3 Year296.5%296.5%12.6%4.7%44.6%35.2%
5 Year338.9%338.9%22.9%9.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Zogenix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

3 weeks ago | Simply Wall St

Have Insiders Been Selling Zogenix, Inc. (NASDAQ:ZGNX) Shares?

Valuation

Is Zogenix undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Zogenix's share price is below the future cash flow value, and at a moderate discount (> 20%).

Zogenix's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Zogenix is loss making, we can't compare its value to the US Pharmaceuticals industry average.

Zogenix is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Zogenix, we can't assess if its growth is good value.


Price Based on Value of Assets

Zogenix is overvalued based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Zogenix expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

69.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Zogenix's revenue is expected to grow significantly at over 20% yearly.

Zogenix's earnings are expected to grow significantly at over 20% yearly.

Zogenix's revenue growth is expected to exceed the United States of America market average.

Zogenix's earnings growth is expected to exceed the United States of America market average.

Zogenix's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Zogenix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Zogenix performed over the past 5 years?

-49.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Zogenix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Zogenix's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Zogenix's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Zogenix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Zogenix has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Zogenix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Zogenix's financial position?


Financial Position Analysis

Zogenix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Zogenix's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Zogenix has no debt.

Zogenix has no debt compared to 5 years ago when it was 3.4%.


Balance Sheet

Low level of unsold assets.

Zogenix has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Zogenix has sufficient cash runway for more than 3 years based on current free cash flow.

Unable to confirm if Zogenix has at least 1 year of cash runway based on growing free cash flows without relevant data.


Next Steps

Dividend

What is Zogenix's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Zogenix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Zogenix's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Zogenix has not reported any payouts.

Unable to verify if Zogenix's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Zogenix has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Zogenix's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Zogenix's salary, the management and board of directors tenure and is there insider trading?

5.8yrs

Average management tenure


CEO

Steve Farr (60yo)

4.4yrs

Tenure

US$6,650,252

Compensation

Dr. Stephen J. Farr, also known as Steve, Ph.D., co-founded Zogenix, Inc. in 2006 and has been its President since May 2006 and its Chief Executive Officer since April 2015. Dr. Farr served as the Chief Op ...


CEO Compensation Analysis

Steve's remuneration is higher than average for companies of similar size in United States of America.

Steve's compensation has increased whilst company is loss making.


Management Age and Tenure

5.8yrs

Average Tenure

56yo

Average Age

The average tenure for the Zogenix management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

11.3yrs

Average Tenure

61.5yo

Average Age

The average tenure for the Zogenix board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$3,179,47615 Mar 19
Roger Hawley
EntityIndividual
Shares60,000
Max PriceUS$53.10
SellUS$826,91017 Dec 18
Roger Hawley
EntityIndividual
Shares20,000
Max PriceUS$41.35
SellUS$61,77227 Nov 18
Erle Mast
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,468
Max PriceUS$42.08

Ownership Breakdown


Management Team

  • Steve Farr (60yo)

    Co-Founder

    • Tenure: 4.4yrs
    • Compensation: US$6.65m
  • Bret Megargel (50yo)

    Vice President of Corporate Development

    • Tenure: 13.1yrs
  • John Turanin (61yo)

    VP & GM of Zogenix Technologies

    • Tenure: 13.3yrs
    • Compensation: US$326.24k
  • Mike Smith (51yo)

    Executive VP

    • Tenure: 2.7yrs
    • Compensation: US$1.99m
  • Bradley Galer (57yo)

    Executive VP & Chief Medical Officer

    • Tenure: 5.8yrs
    • Compensation: US$2.55m
  • Stephen Jenner (51yo)

    Vice President of Marketing

    • Tenure: 8.7yrs
  • Gail Farfel (55yo)

    Executive VP & Chief Development Officer

    • Tenure: 4.2yrs
    • Compensation: US$2.36m
  • Jeff Durflinger (58yo)

    Vice President of Technical Operations & Product Supply

    • Tenure: 8.5yrs
  • Catherine O'Connor

    Senior Director of Corporate Communications

    • Tenure: 0yrs
  • Ashish Sagrolikar

    Executive VP & Chief Commercial Officer

    • Tenure: 1.2yrs
    • Compensation: US$4.35m

Board Members

  • Lou Bock (54yo)

    Independent Director

    • Tenure: 13.1yrs
    • Compensation: US$477.90k
  • Cam Garner (71yo)

    Co-founder & Chairman

    • Tenure: 13.1yrs
    • Compensation: US$517.90k
  • Steve Farr (60yo)

    Co-Founder

    • Tenure: 4.4yrs
    • Compensation: US$6.65m
  • Erle Mast (57yo)

    Independent Director

    • Tenure: 11.3yrs
    • Compensation: US$487.90k
  • Jim Breitmeyer (65yo)

    Director

    • Tenure: 5.5yrs
    • Compensation: US$465.40k
  • Mark Wiggins (63yo)

    Independent Director

    • Tenure: 8.3yrs
    • Compensation: US$475.40k
  • David Brushwood

    Member of External Safe Use Board

    • Tenure: 5.2yrs
  • Jeff Gudin

    Chairperson of External Safe Use Board

    • Tenure: 0yrs
  • John Burke

    Member of External Safe Use Board

    • Tenure: 0yrs
  • Debra Gordon

    Member of External Safe Use Board

    • Tenure: 0yrs

Company Information

Zogenix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zogenix, Inc.
  • Ticker: ZGNX
  • Exchange: NasdaqGM
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.833b
  • Shares outstanding: 44.25m
  • Website: https://www.zogenix.com

Number of Employees


Location

  • Zogenix, Inc.
  • 5858 Horton Street
  • Suite 455
  • Emeryville
  • California
  • 94608
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZGNXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDNov 2010
Z081DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2010
0M3OLSE (London Stock Exchange)YesCommon StockGBUSDNov 2010

Biography

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the F ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 00:17
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.